WO2018133766A1 - 分子定点靶向和激活的激酶抑制剂的制备和用途 - Google Patents

分子定点靶向和激活的激酶抑制剂的制备和用途 Download PDF

Info

Publication number
WO2018133766A1
WO2018133766A1 PCT/CN2018/072766 CN2018072766W WO2018133766A1 WO 2018133766 A1 WO2018133766 A1 WO 2018133766A1 CN 2018072766 W CN2018072766 W CN 2018072766W WO 2018133766 A1 WO2018133766 A1 WO 2018133766A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compound
formula
pabc
pharmaceutically acceptable
Prior art date
Application number
PCT/CN2018/072766
Other languages
English (en)
French (fr)
Inventor
刘源
刘辰
王海洋
Original Assignee
亚飞（上海）生物医药科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 亚飞（上海）生物医药科技有限公司 filed Critical 亚飞（上海）生物医药科技有限公司
Priority to CA3050345A priority Critical patent/CA3050345A1/en
Priority to AU2018209534A priority patent/AU2018209534B2/en
Priority to US16/478,826 priority patent/US11078232B2/en
Priority to EP18741988.2A priority patent/EP3572420B1/en
Publication of WO2018133766A1 publication Critical patent/WO2018133766A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Definitions

  • the present invention relates to the preparation and use of molecularly targeted and activated kinase inhibitors.
  • the saccharide is a polyhydroxy (two or more) aldehyde or ketone compound, and can be an organic compound which is one of the above after hydrolysis.
  • Sugar molecules have different receptors on immune cells and tumor cells.
  • lactose (Lacto) has multiple receptors for action in human cells, including the sialoglycoprotein receptor.
  • the interaction between sugar molecules and receptors serves as an inter-cell recognition and biomolecular recognition, and is involved in important applications such as cell communication.
  • Sorafenib is a new multi-targeted oral drug for the treatment of tumors with the following structural formula:
  • sorafenib As a first-line treatment for advanced renal cell carcinoma for the treatment of inoperable advanced renal cell carcinoma.
  • Solafenib can also be used to treat primary hepatocellular carcinoma that is inoperable or distantly metastatic, as well as to treat patients with locally recurrent or metastatic, progressively differentiated thyroids that are no longer effective for radioiodine therapy.
  • the drug has a certain effect on non-small cell lung cancer as well as melanoma.
  • Solafenib is a small molecule targeted drug with dual anti-tumor effects.
  • Sorafenib is a silk, threonine protein kinase (RAF) and tyrosine kinase inhibitor that inhibits RAF gene expression and inhibits RAF/MEK/ERK signaling pathways from directly inhibiting tumor growth.
  • RAF threonine protein kinase
  • tyrosine kinase inhibitor that inhibits RAF gene expression and inhibits RAF/MEK/ERK signaling pathways from directly inhibiting tumor growth.
  • Blocking tumor angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR-1, VEGFR-2, VEGFR-3) and platelet-derived growth factor receptor beta (PDGFR- ⁇ ), cutting tumor cells
  • VEGFR-1, VEGFR-2, VEGFR-3 vascular endothelial growth factor receptor
  • PDGFR- ⁇ platelet-derived growth factor receptor beta
  • sorafenib has serious adverse reactions, including rash, diarrhea, elevated blood pressure, redness, pain, swelling or blisters in the palms or feet, long-term use of lymphocytes, and is not suitable for basic liver disease. Patients and inhibit human immunity.
  • the present disclosure provides a compound having the structure: or a pharmaceutically acceptable salt thereof:
  • X is a polar and non-polar uncharged amino acid such as alanine, proline or threonine;
  • A is alanine
  • N is asparagine
  • PABC is -NH-phenyl-CH 2 -O-;
  • Z is a drug molecule.
  • the lactobionic acid residue is linked to X by an amide bond (-C(O)-NH-).
  • X and A are attached by an amide bond.
  • PABC is linked to N via an amide bond.
  • PABC is linked to Z by an ester group (-O-C(O)-).
  • Z is selected from the group consisting of doxorubicin, dalafenib, dovetinib, motesani, and the sorafenib derivative of Formula B.
  • the compound of Formula A has the structure of Formula I below:
  • X is alanine
  • the compound of Formula I has the structure of Formula II:
  • the compound of formula II is selected from the group consisting of
  • X is valine
  • the compound of formula I has the structure of formula III:
  • the compound of formula III is selected from the group consisting of
  • X is threonine and the compound of formula I has the structure of formula IV:
  • the compound of formula IV is selected from the group consisting of
  • the present disclosure also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula A as disclosed herein, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition comprises a compound of Formula I or a pharmaceutically acceptable salt thereof.
  • the pharmaceutical composition contains any one or more of the compounds S1-S18 disclosed herein or a pharmaceutically acceptable salt thereof.
  • the present disclosure also provides the use of the compound of formula A or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer or cancer cell metastasis.
  • the cancer is selected from the group consisting of liver cancer, kidney cancer, thyroid cancer, colorectal cancer, bladder cancer, brain cancer, breast cancer, cervical cancer, rectal cancer, esophageal cancer, lung cancer (eg, bronchial lung cancer) , including undifferentiated small cell and non-small cell), nasopharyngeal carcinoma, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, uterine cancer, ovarian cancer, testicular cancer, blood cancer (such as chronic or acute leukemia, including lymphocytic And granulocyte leukemia), malignant lymphoma, cellulosic sarcoma, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma, nephroblastoma, neuroblastoma, thyroid cancer, and head and neck squamous cell carcinoma.
  • lung cancer eg, bronchial lung cancer
  • nasopharyngeal carcinoma pan
  • the present disclosure also provides the use of the compound of formula A or a pharmaceutically acceptable salt thereof for the preparation of an immunotherapeutic agent.
  • the immunotherapeutic agent can be used to stimulate T cell proliferation and invasion of a lesion, inhibit tumor-associated macrophages, and/or promote a stimulatory immune response.
  • R is H or halogen
  • the compound of formula B is selected from the group consisting of compound a and compound b, ie:
  • X is a polar and non-polar uncharged amino acid such as alanine, proline or threonine;
  • A is alanine
  • N is asparagine
  • PABC ' is -NH- phenyl group -CH 2 -OH.
  • the lactobionic acid residue is linked to X by an amide bond (-C(O)-NH-).
  • X and A are attached by an amide bond.
  • Formula C has the structure shown by Formula C-1:
  • Also provided herein is the use of a compound of formula C for increasing the anticancer activity of an anticancer drug.
  • Figure 1 Targeted targeting of molecules results in the same distribution of highly activated and efficient molecular receptors on the surface of tumor cells. Fluorescence confocal microscopy for detection of antibody-tagged MDA-MB435 tumor cells, aspartate endopeptidase (left 1, green), sialoglycoprotein receptor (left 2, red), DAPI (blue) Color), the two figures merge and are yellow (left 3).
  • FIG. 1 S3 has more tumor tissue distribution and penetration after intravenous injection than Succinyl-AANL-DOX.
  • Figure 3 Toxic effects of S1, sorafenib and compound a on Heg2 tumor cells.
  • Figure 4 Molecular site-directed targeting results in a high activation and high efficiency distribution of compounds S1, S2, S3 and C11 relative to sorafenib tumor tissue.
  • Figure 5 Molecular site-directed targeting in tumor therapy results in a tumor size change curve for highly activated and highly potent compounds S1, S2, S3, S4, S5, S6, sorafenib and doxorubicin.
  • FIG. 6 Differentiation of bone marrow cells by cell is M1, M2 type macrophages, and asparagine endopeptidase is highly expressed and secreted on M2 type.
  • the left panel shows tumor-induced M2 macrophages, and the right panel shows M1-inflammatory macrophages.
  • the bright spot (green fluorescence) is the staining of the asparagine endopeptidase.
  • Figure 7 Comparison of the toxicity of drugs to M2 tumor-associated macrophages.
  • Figure 8 Schematic diagram of the mechanism of action of the compounds herein.
  • the sialoglycoprotein receptor and the aspartate endopeptidase molecular receptor are co-distributed on the surface of tumor cells, and the same distribution of double targets may be targeted to cause high activation of highly active compounds.
  • Reasons; the characteristics of this co-distribution can be used to design drugs to accumulate and retain in the co-distribution position, thereby improving the recognition and activation efficiency of tumor cells.
  • the present inventors linked a specific asparagine endopeptidase (Legumain) substrate to a different type of saccharide, and tested the stability and enzymatic cleavage efficiency of the linker. Linkers with strong activation effects and relatively high stability were predicted.
  • the present inventors used the selected linker to ligate different drug molecules to obtain the compound of the present formula A. These compounds are molecularly targeted to result in highly active and highly potent compounds, the mechanism of action of which is shown in Figure 8:
  • the targeted site targeting of the present disclosure results in high activation and high potency compounds that are efficiently activated by the same distribution of dual targets to kill
  • the characteristics of cancer cells also have the characteristics of inhibiting M2 type tumor-associated macrophages by endocytosis and then activating anti-tumor immunity, and finally produce an activity that cures tumors, produces immunity, and causes tumors to not recur.
  • X is a polar and non-polar uncharged amino acid such as alanine, valine or threonine; A is alanine; N is asparagine; PABC' is -NH-phenyl -CH 2 -OH.
  • lactobionic acid residues (Lacto), X and N amide linkages are attached, and PABC' is also attached to the asparagine residue (N) via an amide linkage.
  • N in "-NH-” as a group means a nitrogen atom
  • N as an amino acid residue means asparagine.
  • the amide bond means "-C(O)-NH-”.
  • Formula C has the structure shown by Formula C-1:
  • the compound of formula C can be targeted as a molecule of the present disclosure to result in a linker moiety in a highly activated and highly potent compound for attachment to an active drug molecule.
  • the targeted site targeting of the present invention results in a highly activated and highly potent compound having the structure shown in Formula A below:
  • X is a polar and non-polar uncharged amino acid such as alanine, valine or threonine; A is alanine; N is asparagine; PABC is -NH-phenyl- CH 2 -O-; Z is a drug molecule of interest.
  • lactobionic acid residues, XAN and PABC are each linked via an amide bond, while PABC is linked to Z by an ester group (-O-C(O)-).
  • the structure of the compound of Formula A is further as shown in Formula I disclosed herein.
  • the drug molecule Z of interest may be selected from the sorafenib derivatives shown by the following formula B:
  • R is H or halogen
  • halogen includes F, Cl, Br, and I.
  • the compound of Formula B is selected from Compound a and Compound b disclosed herein.
  • the drug molecule Z of interest may also be, for example, doxorubicin, darafini, dovetinib and motesani.
  • the site to which the PABC is attached can be determined based on the pharmacodynamic structure of the drug molecule of interest. It is usually connected to the PABC at a position away from its active site.
  • the manner of connection can be in any suitable manner.
  • the drug molecule is linked to PABC via an ester group, ie, -O-C(O)-.
  • X is alanine, valine or threonine
  • Formula A may be a lactobionic acid residue - AAN-PABC-Z, a lactobionic acid residue - VAN-PABC-Z Or lactobionic acid residue - TAN-PABC-Z.
  • X is alanine, and thus, the structure of the compound of Formula I herein can be as shown in Formula II.
  • X is a proline, and thus, the structure of the compound of Formula I herein can be as shown in Formula III.
  • X is threonine, such that the structure of the compound of Formula I herein can be as shown in Formula IV.
  • Exemplary compounds of Formula A or Formula I herein can be as indicated by S1-S18 as previously described.
  • pharmaceutically acceptable salts of the compounds of Formula A or Formula I herein include, but are not limited to, mineral acid salts and organic acid salts such as hydrochlorides, hydrobromides, phosphates, sulfates, citrates, lactates, tartrates, maleic acid. Salts, fumarates, methanesulfonates, mandelates and oxalates; and with bases such as sodium hydroxy, tris(hydroxymethyl)aminomethane (TRIS, tromethamine) and N-methyl gluco An inorganic base salt and an organic base salt formed by a sugar amine.
  • the drug molecule Z in Formula A is a mesylate salt of darabifen, a compound of formula B, or a hydroxypropionate salt of dovetinib or the like.
  • stereoisomers of a compound of Formula A or Formula I are also included herein.
  • the individual enantiomers can be separated according to methods well known to those skilled in the art. It will be understood, however, that among the compounds described herein, lactobionic acid and X, A and N are preferably in their naturally occurring isomeric form.
  • the preparation scheme for some of the compounds herein can be as shown in Examples 1-3 herein.
  • the XAN-PABC-Z moiety of the compound of formula A can be synthesized first, followed by the lactobionic acid; alternatively, the lactobionic acid residue -XAN-PABC moiety of the compound of formula A can be synthesized first, followed by the drug molecule of interest. Z is connected.
  • composition comprising a compound of formula A, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers are generally safe, non-toxic, and broadly include any known materials in the pharmaceutical industry for the preparation of pharmaceutical compositions, such as fillers, diluents, coagulants, binders, lubricants, Glidants, stabilizers, colorants, wetting agents, disintegrating agents, and the like.
  • Suitable pharmaceutically acceptable carriers include sugars such as lactose or sucrose, mannitol or sorbitol; cellulose preparations and/or calcium phosphates such as tricalcium phosphate or dibasic calcium phosphate; starch pastes including corn starch, wheat Starch, rice starch, potato starch, gelatin, tragacanth, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; silica, talc, stearic acid or a salt thereof, Such as magnesium stearate or calcium stearate and / or polyethylene glycol; and so on.
  • a pharmaceutically acceptable carrier it is primarily necessary to consider the mode of administration of the pharmaceutical composition, as is well known to those skilled in the art.
  • the pharmaceutical composition may contain a therapeutically effective amount of a compound of formula A or a pharmaceutically acceptable salt thereof.
  • effective amount is meant an amount of a component sufficient to produce the desired reaction.
  • the specific effective amount depends on a number of factors, such as the particular condition being treated, the patient's physical condition (eg, patient weight, age, or sex), duration of treatment, co-administered therapy (if any), and specific formula. "Effective amount” also means that the toxic or negative effect of the polypeptide of the present application is less than the positive effect brought about by this amount.
  • a therapeutically effective amount of a compound of formula A, or a pharmaceutically acceptable salt thereof can be comparable to a therapeutically effective amount of a conventional pharmaceutical molecule Z.
  • the treatment of a compound of the present disclosure, or a pharmaceutically acceptable salt thereof is therapeutic due to the coupling of a linker of the present disclosure (ie, a compound of formula C) with higher activation efficiency and anti-tumor effects.
  • the effective amount is lower than the therapeutically effective amount of the conventional drug molecule Z.
  • compositions can be prepared according to known pharmaceutical procedures, such as Remington's Pharmaceutical Sciences (17th edition, edited by Alfonoso R. Gennaro, Mack Publishing Company, Easton) , Pennsylvania (1985)) has a detailed record in the book.
  • compositions of the present disclosure may be in a variety of suitable dosage forms including, but not limited to, tablets, capsules, injections, and the like, and may be administered by any suitable route to achieve their intended purpose.
  • it can be administered by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intrathecal, intracranial, nasal or topical routes.
  • the dosage of the drug can be determined according to the age, health and weight of the patient, the type of concurrent treatment, and the frequency of treatment.
  • compositions of the present disclosure can be administered to any mammal, especially a human.
  • the compounds of formula A herein, or pharmaceutically acceptable salts or pharmaceutical compositions thereof are especially useful for treating cancer or cancer cell metastasis.
  • a cancer that can be treated with a compound of formula A herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof can depend on the therapeutic activity of the drug molecule Z of interest itself.
  • sorafenib is a multi-targeted tumor treatment drug, and its indications include, but are not limited to, liver tumor cells that cannot be operated or distantly metastasized, inoperable kidney tumor cells, and no treatment for radioactive iodine. Re-effective local recurrence or metastatic, progressive differentiation of thyroid patients.
  • Adriamycin has a broad spectrum of anti-tumor, suitable for acute leukemia (lymphocytic and granulocyte), malignant lymphoma, breast cancer, bronchial lung cancer (undifferentiated small cell and non-small cell), ovarian cancer, soft tissue sarcoma Osteogenic sarcoma, rhabdomyosarcoma, Ewing sarcoma, nephroblastoma, neuroblastoma, bladder cancer, thyroid cancer, prostate cancer, head and neck squamous cell carcinoma, testicular cancer, stomach cancer and liver cancer.
  • acute leukemia lymphocytic and granulocyte
  • malignant lymphoma breast cancer
  • bronchial lung cancer undifferentiated small cell and non-small cell
  • ovarian cancer soft tissue sarcoma Osteogenic sarcoma, rhabdomyosarcoma, Ewing sarcoma, nephroblastoma, neuroblastoma, bladder cancer, thyroid
  • a cancer of the formula A or a pharmaceutically acceptable salt or pharmaceutical composition thereof for use in therapy includes, but is not limited to, liver cancer, kidney cancer, thyroid cancer, colorectal cancer, bladder cancer, brain cancer, breast cancer, cervical cancer. , rectal cancer, esophageal cancer, lung cancer (such as bronchial lung cancer, including undifferentiated small cell and non-small cell), nasopharyngeal cancer, pancreatic cancer, prostate cancer, skin cancer, stomach cancer, uterine cancer, ovarian cancer, testicular cancer, Blood cancer (eg chronic or acute leukemia, including lymphocytic and granulocyte leukemia), malignant lymphoma, fibrosarcoma, soft tissue sarcoma, osteosarcoma, rhabdomyosarcoma, Ewing's sarcoma, nephroblastoma, neuroblastoma, Thyroid cancer and squamous cell carcinoma of the head and neck.
  • the compounds of Formula A can also stimulate T cell proliferation and invasion of the foci, inhibit tumor-associated macrophages, and/or promote a stimulatory immune response.
  • the present disclosure provides a method of treating cancer or cancer cell metastasis comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula A, or a pharmaceutically acceptable salt or pharmaceutical composition thereof, disclosed herein.
  • the cancer or cancer cell metastasis is as described above.
  • the present disclosure also provides a method of stimulating T cell proliferation and invasion of a lesion, inhibiting tumor-associated macrophages, and/or promoting a stimulatory immune response, the method comprising administering to a subject in need thereof therapeutically effective An amount of a compound of formula A as disclosed herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.
  • the "object" of interest can be any mammal, especially a human.
  • a compound of the formula A or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of cancer or cancer cell metastasis, or for the preparation of an immunotherapeutic medicament.
  • the cancer or cancer cell metastasis is as described above; the immunotherapeutic agent can be used to stimulate T cell proliferation and invasion of the lesion, inhibit tumor-associated macrophages, and/or promote a stimulatory immune response.
  • L-Ala-L-Ala-L-Asn(Trt)-PABC (6.21 g, 10 mmol), DMF (20 ml), DIPEA (1.29 g, 10 mmol) was sequentially added. After stirring at room temperature for 5 minutes, the system was cooled to 0 ° C by ice salt bath. Allyl chloroformate (1.21 g, 10 mmol) was added slowly and stirred at room temperature overnight.
  • the lactobionic acid (3.8 g, 10 mmol) was dissolved in anhydrous methanol (100 ml), and the mixture was warmed to reflux.
  • QHL010 (175 mg, 0.192 mmol) was dissolved in anhydrous methanol (10 ml), and added dropwise to the above-mentioned lactic acid in methanol. After the dropwise addition was completed, the system was warmed to 60 ° C and allowed to react overnight. The solvent was evaporated to dryness crystals crystals crystals crystals crystals crystals crystals crystals
  • the lactobic acid (3.8 g, 10 mmol) was dissolved in anhydrous methanol (100 ml), and the mixture was warmed to reflux.
  • QHL018 (175 mg, 0.188 mmol) was dissolved in anhydrous methanol (10 ml) and added dropwise to a solution of the above-mentioned lactic acid in methanol. After the dropwise addition was completed, the system was warmed to 60 ° C and allowed to react overnight. The solvent was evaporated to dryness crystals crystals crystals crystals crystals crystals crystals
  • the compounds S3-S6, S9-S11 and S15-S18 were synthesized by the following scheme, wherein X is alanine, threonine or valine.
  • the amino terminus of X in XAN-PABC is first reacted with the carboxyl group of lactobionic acid to form a site-directed targeting linker (Lacto-XAN-PABC).
  • the Lacto-XAN-PABC is then activated to generate Lacto-XAN-PABC-PNP.
  • Compound Z is subjected to a nucleophilic reaction with Lacto-XAN-PABC-PNP with an amino group contained in its structure to obtain a compound Lacto-XAN-PABC-Z.
  • the lactobic acid (3.8 g, 10 mmol) was dissolved in anhydrous methanol (100 ml), and the mixture was warmed to reflux.
  • MS detection results confirmed that the S1-S18 compound had a molecular weight as shown in Table 1 below, which was consistent with the molecular weight predicted by the structural calculation.
  • Example 4 Targeted targeting of molecules leads to synthetic screening of highly activated linker components
  • the tumor tissue-specific activation site is a short peptide, because the enzyme activity center of the aspartic endopeptidase is located at the bottom of the balloon-like invagination, and the cleavage site needs to be close to the enzyme activity center. Whether or not the point has steric hindrance becomes very important.
  • lactobionic acid-AAN-p-aminobenzyl alcohol of the present invention not only does not affect the activation efficiency, but promotes the activation efficiency and stability as compared with PEG-Ala-Ala-ASN-p-aminobenzyl alcohol.
  • Example 5 Cellular distribution characteristics of sialic acid glycoprotein receptor and aspartate endopeptidase
  • the inventors have intensively studied that the sialic acid glycoprotein receptor and the aspartic endopeptidase molecular receptor are co-distributed on the surface of tumor cells. Specifically, in the immunofluorescence staining of MDA-MB435 breast cancer tumor cells, the corresponding antibody-labeled sialoglycoprotein receptor and aspartic endopeptidase were detected by fluorescence confocal microscopy, and DAPI was used for nuclear staining. As a result, as shown in Fig. 1, the distribution of the sites of the sialic acid glycoprotein receptor and the aspartic endopeptidase was the same. This co-distribution feature allows the compounds of the invention to accumulate and remain in a co-distributed position, thereby increasing their efficiency in recognition and activation of tumor cells.
  • Example 6 Tissue distribution characteristics of the compounds of the invention
  • Sorafenib does not have the potential to be coupled to a compound of formula II of the invention.
  • this paper has carried out allosteric synthesis and screening of the ortho-carboxamide group of the pyridine ring in the sorafenib molecule, and obtained a special compound that satisfies both the structure-activity relationship and the release effect.
  • Compound a and compound b The stability and cell viability experiments of compound a and compound b showed that compound a and compound b were stable in weak acid, weak base and neutral buffer system, did not degrade, and inhibited cancer cells.
  • Better than the positive control drugs sorafenib and regorafenib Figure 3).
  • Example 8 Antitumor cytotoxicity of S1 and Compound a
  • the logarithmic Heg2 cells were collected, the cell suspension concentration was adjusted, 140 ul per well was added, and the cells were plated to a density of ⁇ 5000 cells/well; 5% CO 2 was incubated at 37 ° C overnight until the cell monolayer was covered with the bottom of the well ( 96 well flat bottom plate), and then add different concentrations of compound S1, compound a and sorafenib with continuous concentration gradient.
  • the drug is set with 9 concentration gradients, 10ul per well, and 3 duplicate wells; 5% CO 2 , 37 Incubate for 48 hours at °CPH6.5, observe under an inverted microscope; add 20 ul of MTT solution (5 mg/ml, ie 0.5% MTT) to each well and continue to culture for 4 h.
  • the sample compound and a portion of the control compound (herein, all of the control compounds can be synthesized by a method similar to that described in Examples 1-3) were uniformly diluted 10-fold to 1 mg/ml with the enzyme-cutting solution.
  • 1 mg/ml of the sample compound was added to the aspartic endopeptidase (1 umol/L, pH 6.0) at 37 ° C for 2 hours.
  • the enzyme was able to release the enzyme.
  • the product was cut, and the decrease in the compound and the increase in the product were examined by HPLC to compare the enzyme activation efficiency (the ratio of the product released by the enzyme cleavage to the original compound).
  • the results are shown in Table 3 below.
  • S1 has a higher activation efficiency than C5, indicating that compounds a, b are more suitable for Lacto-AAN-PABC-linkers than paclitaxel.
  • the activation efficiencies of S1, S7 and S13 increased in turn, while other amino acid substitutions such as C10 did not activate, indicating that the amino acid screening optimized linker has an important role in optimizing the overall drug activation.
  • the activation efficiency of S3 is higher than that of C11, indicating that the linker of the present invention can improve the activation efficiency of the drug.
  • the test was carried out by leaving it at 60 ° C for 10 days in the dark.
  • the ratio of the change in the content of the compound to the compound at time 0 was measured by HPLC, and the stability value (%) was calculated.
  • the results are shown in Table 4 below.
  • Example 11 Metabolic distribution of the compounds herein relative to sorafenib and other drugs of attachment
  • the tumor tissue homogenate was obtained by intravenous injection of 10 micromoles per kilogram of the drug into the tumor-bearing mice, and the drug content was determined by the HPCL method. As a result, as shown in Fig. 4, it was confirmed that the compounds S1 and S2 were multiplied in the distribution of sorafenib in the tumor, and the compound S3 also had a property of increasing the distribution in the tumor compared to C11.
  • Example 12 Toxicology of the compounds herein relative to sorafenib and other attachment means
  • OBJECTIVE To determine the acute toxicity of highly activated compounds by targeted targeting of the present invention by measuring the MTD (maximum tolerated dose) experiment in mice.
  • Test drugs The test drugs are shown in Table 3 below. The injections of each drug and the control drug were uniformly dissolved using water for injection, and diluted to the corresponding dose with physiological saline during the test.
  • mice Primary BA competition (BALB/C) mice (purchased from Shanghai Shrek Biotechnology Co., Ltd.), weighing 19-21 g, female.
  • mice Thirty-six BALB/C mice, weighing 19-21 g, were randomly divided into groups according to body weight, with 10 rats in each group. As shown in Table 3, the different doses of the drug in Table 3 were dissolved in physiological saline, intravenously, and the dose at the time of death and the maximum tolerated dose (MTD) were recorded. A control test of the saline group and the doxorubicin group injection (commercially available, Beijing Yuekang) was carried out, and the volume of each mouse was 0.2 ml. After 17 consecutive days of observation, the animals were observed daily for erect, really, lethargic, hunched, overactive, and recorded weight and death.
  • MTD maximum tolerated dose
  • Table 5 Mortality results of different doses of S1, S2, S3, S4, S5 and S6 injections and saline and doxorubicin injections in the test mice
  • Group Death dose (mg/kg) MTD (mg/kg) Number of deaths (only) Saline Equal volume 0 S1 350 300 1 S2 350 300 2 S3 110 100 1 S4 300 280 2 S5 320 310 2 S6 290 280 1 S7 345 300 1 S8 340 280 2 S9 120 100 2 S10 320 310 1 S11 330 300 2 S12 300 290 1 S13 360 320 2
  • Example 13 Efficacy of the compounds herein relative to sorafenib and other attachment means
  • Example 14 Immunotherapy of a compound of the present invention relative to a control group such as sorafenib
  • D121 lung cancer cells derived from the American model culture collection reservoir ATCC were cultured in DMEM medium containing 10% fetal bovine serum, and the cells were digested with EDTA trypsin according to routine use, and passed two to three times a week for placement. Incubate at 37 ° C in a 5% CO 2 incubator.
  • mice were intraperitoneally injected with 100 ⁇ L of 5 ⁇ 10 5 D121 lung cancer cells that had died by repeated freeze-thaw cycles, and immunized 3 times with an interval of 2 weeks.
  • Treatment process i.v., S1 ⁇ S8 use 1 / 6 MTD dose once a week for 4 weeks.
  • the immunosuppressive regulatory point protein Anti-Pd L1 antibody was injected twice a week. A total of two weeks.
  • Tumor tissues were ground and single cell cells were isolated by filtration using Cell starainer 40 ⁇ m Nylon cell strainer, lysed twice with blood cell lysate for 20 min, washed twice with 1% BSA-PBS buffer, centrifuged, and resuspended. Perform cell counting. 1 ⁇ 10 5 cells were incubated with the white blood cell common antigen CD45-PE and CD8-FITC-labeled antibody at room temperature for 1 hour in the dark, and then the T lymphocyte antigen in leukocyte common antigen (CD45)-positive cells was analyzed by flow cytometry ( The proportion of CD8) positive cells.
  • Example 15 New advances in the compounds of this study relative to sorafenib in the CT26 immunotherapy model
  • CT26 tumor cells were purchased from the American Type Culture Collection ATCC, and the cells were cultured using a 10% fetal bovine serum DMEM medium at 37 ° C, 5% carbon dioxide. The cells were passaged every 3 days and the cells were used within 15 generations. Animals: C57 mice, 6-8 weeks old, all female, purchased from Shanghai Slack Laboratory Animal Co., Ltd.
  • Tumor production 10 6 live CT26 tumor cells were injected subcutaneously into the back of tumor-immunized C57 mice, and treatment was started when the tumor grew to about 0.3-0.4 cm, and the tumor size (mm 3 ) was recorded. The tumor inhibition rate on day 42 was calculated as compared to the vehicle control group.
  • Treatment process IV injection is used, and the drug is used at a dose of 1/3 MTD once a week. Immunosuppressive IV injection treatment once a week for a total of 6 weeks of treatment.
  • Tumor-associated macrophages are an accomplice to tumor growth and recurrence. Inflammatory macrophages (M1 type) and tumor-associated macrophages (M2 type) were induced, and tumor-associated macrophages (M2 type) were highly expressed by fluorescent staining to express asparagine endopeptidase (Fig. 6).
  • M2 type Tumor-associated macrophages induced by mononuclear bone marrow cells were collected by M-CSF (10 ng/ml), and the cell suspension concentration was adjusted. 140 ul per well was added, and the cells were adjusted to a density of ⁇ 3000 cells.
  • the culture was terminated, and the culture solution in the well was carefully aspirated; 100 ul of dimethyl sulfoxide was added to each well, and shaken on a shaker at a low speed for 10 min to dissolve the crystals sufficiently.
  • the absorbance of each well was measured at an enzyme-linked immunosorbent detector at OD490nm.
  • zero adjustment holes medium, MTT, dimethyl sulfoxide
  • control group cell, same concentration of drug dissolution medium, medium, MTT, dimethyl sulfoxide
  • the toxicity of the compound to tumor-associated macrophages (M2 type) was analyzed after the test.
  • the inhibition of tumor-associated macrophages (M2 type) by different drugs was compared. The results are shown in Fig.
  • Figure 7 shows that the lactose-containing drug (S1) is more susceptible to phagocytosis and activation by macrophages than other methods of attachment.
  • Compound a, sorafenib, is also toxic because it is not a targeted activating drug.
  • molecular targeted targeting results in a highly activated and highly efficient linker with a specific role in promoting tumor-associated macrophage (M2 type) phagocytosis and activating drugs, thereby inhibiting tumor-associated macrophages (M2 type).
  • Example 17 Pharmacodynamics and immunotherapy of compounds S4-S6, S9-S12 and S15-S18 in a CT26 treatment model
  • the CT26 immunotherapy model was constructed as in Example 15, and the pharmacodynamic and immunotherapeutic effects of the compounds S4-S6, S9-S12 and S15-S18 in the CT26 treatment model were tested. The results are shown in Table 8 below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

公开了分子定点靶向和激活的激酶抑制剂的制备和用途。具体而言，公开了式：乳糖酸残基-XAN-PABC-Z 所示的化合物或其药学上可接受的盐，式中，X为极性和非极性不带电荷的氨基酸，如丙氨酸、缬氨酸或苏氨酸；A为丙氨酸；N为天冬酰胺；PABC为-NH-苯基-CH 2-O-；和Z为药物分子；其中，乳糖酸残基、XAN以及PABC相互间通过酰胺键相连；PABC与Z以酯基，即-O-C(O)-相连。

Description

分子定点靶向和激活的激酶抑制剂的制备和用途 技术领域
本发明涉及分子定点靶向和激活的激酶抑制剂的制备和用途。
背景技术
糖类物质是多羟基(2个或以上)的醛类或酮类化合物，在水解后能变成以上两者之一的有机化合物。糖分子在免疫细胞和肿瘤细胞上有着不同的受体。例如，乳糖(Lacto)在人体细胞中具有多种作用受体，其中包括唾液酸糖蛋白受体。糖分子与受体间相互作用起到了细胞间识别和生物分子间的识别，参与细胞通信等重要用途。
索拉菲尼(Sorafenib)是一种新型多靶向性的治疗肿瘤的口服药物，其结构式如下所示：
Figure PCTCN2018072766-appb-000001
2005年12月20日，美国FDA快速批准了索拉菲尼作为晚期肾细胞癌的一线治疗药物，用于治疗不能手术的晚期肾细胞癌。索拉菲尼还可用于治疗无法手术或远处转移的原发肝细胞癌，以及治疗对放射性碘治疗不再有效的局部复发或转移性、逐步分化型甲状腺患者。此外，该药对非小细胞肺癌以及黑色素瘤也有一定疗效。索拉菲尼是一种小分子靶向药物，具有双重抗肿瘤作用。主要作用机制是：1)索拉菲尼是丝、苏氨酸蛋白激酶(RAF)和酪氨酸激酶抑制剂，通过抑制Ras基因的表达，抑制RAF/MEK/ERK信号传导通路直接抑制肿瘤生长；2)通过抑制血管内皮生长因子受体(VEGFR-1，VEGFR-2，VEGFR-3)和血小板源性生长因子受体β(PDGFR-β)而阻断肿瘤新生血管的形成，切断肿瘤细胞的营养供应而达到抑制肿瘤生长的目的。但是索拉菲尼具有严重的不良反应，包括皮疹、腹泻、血压升高以及手掌或足底部发红、疼痛、肿胀或出现水疱，长期服用淋巴细胞下降，并且不适用于本身具有基础肝脏疾病的患者和抑制人体免疫力。
发明内容
本公开提供具有以下结构的化合物或其药学上可接受的盐：
乳糖酸残基-XAN-PABC-Z   (式A)
式中，
X为极性和非极性不带电荷的氨基酸，如丙氨酸、缬氨酸或苏氨酸；
A为丙氨酸；
N为天冬酰胺；
PABC为-NH-苯基-CH 2-O-；
Z为药物分子。
在一个或多个实施方案中，乳糖酸残基与X以酰胺键(-C(O)-NH-)相连。
在一个或多个实施方案中，X与A以酰胺键相连。
在一个或多个实施方案中PABC与N通过酰胺键相连。
在一个或多个实施方案中，PABC与Z以酯基(-O-C(O)-)相连。
在一个或多个实施方案中，Z选自阿霉素、达拉非尼、多韦替尼、莫特塞尼和本公开式B所示的索拉菲尼衍生物。
在一个或多个实施方案中，式A化合物具有下式I所示的结构：
Figure PCTCN2018072766-appb-000002
式中，X和Z如前文所定义。
在一个或多个实施方案中，X为丙氨酸，所述式I化合物具有下式II所示的结构：
Figure PCTCN2018072766-appb-000003
在一个具体实施例中，所述式II化合物选自：
S1：Lacto-AAN-PABC-化合物a
Figure PCTCN2018072766-appb-000004
S2：Lacto-AAN-PABC-化合物b
Figure PCTCN2018072766-appb-000005
S3：Lacto-AAN-PABC-阿霉素
Figure PCTCN2018072766-appb-000006
S4：Lacto-AAN-PABC-达拉非尼
Figure PCTCN2018072766-appb-000007
S5：Lacto-AAN-PABC-多韦替尼
Figure PCTCN2018072766-appb-000008
S6：Lacto-AAN-PABC-莫特塞尼
Figure PCTCN2018072766-appb-000009
在一个具体实施例中，X为缬氨酸，所述式I化合物具有下式III结构：
Figure PCTCN2018072766-appb-000010
在一个具体实施例中，所述式III化合物选自：
S7：Lacto-VAN-PABC-化合物a
Figure PCTCN2018072766-appb-000011
S8：Lacto-VAN-PABC-化合物b
Figure PCTCN2018072766-appb-000012
S9：Lacto-VAN-PABC-阿霉素
Figure PCTCN2018072766-appb-000013
S10：Lacto-VAN-PABC-达拉非尼
Figure PCTCN2018072766-appb-000014
S11：Lacto-AAN-PABC-多韦替尼
Figure PCTCN2018072766-appb-000015
S12：Lacto-VAN-PABC-莫特塞尼
Figure PCTCN2018072766-appb-000016
在一个具体实施例中，X为苏氨酸，所述式I化合物具有下式IV结构：
Figure PCTCN2018072766-appb-000017
在一个具体实施例中，所述式IV化合物选自：
S13：Lacto-TAN-PABC-化合物a
Figure PCTCN2018072766-appb-000018
S14：Lacto-TAN-PABC-化合物b
Figure PCTCN2018072766-appb-000019
S15：Lacto-TAN-PABC-阿霉素
Figure PCTCN2018072766-appb-000020
S16：Lacto-TAN-PABC-达拉非尼
Figure PCTCN2018072766-appb-000021
S17：Lacto-TAN-PABC-多韦替尼
Figure PCTCN2018072766-appb-000022
S18：Lacto-TAN-PABC-莫特塞尼
Figure PCTCN2018072766-appb-000023
本公开还提供一种药物组合物，所述药物组合物含有本文所公开的式A化合物或其药学上可接受的盐，和药学上可接受的载体。
在一个或多个实施方案中，所述药物组合物含有式I所示的化合物或其药学上可接受的盐。
在一个或多个实施方案中，所述药物组合物含有本文所公开的化合物S1－S18中的任意一种或多种或其药学上可接受的盐。
本公开还提供所述式A化合物或其药学上可接受的盐在制备治疗癌症或癌细胞转移用的药物中的应用。
在一个或多个实施方案中，所述癌症选自：肝癌、肾癌、甲状腺癌、结肠直肠癌、膀胱癌、脑癌、乳腺癌、宫颈癌、直肠癌、食管癌、肺癌(例如支气管肺癌，包括未分化小细胞性和非小细胞性)、鼻咽癌、胰腺癌、前列腺癌、皮肤癌、胃癌、子宫癌、卵巢癌、睾丸癌、血癌(例如慢性或急性白血病，包括淋巴细胞性和粒细胞性白血病)、恶性淋巴瘤、纤维素肉瘤、软组织肉瘤、成骨肉瘤、横纹肌肉瘤、尤文肉瘤、肾母细胞瘤、神经母细胞瘤、甲状腺癌和头颈部鳞癌。
本公开还提供所述式A化合物或其药学上可接受的盐在制备免疫治疗药物中的应用。
在一个或多个实施方案中，所述免疫治疗药物可用于刺激T细胞的繁殖和对病灶 的侵入、抑制肿瘤相关巨噬细胞和/或促进刺激免疫反应。
本文还提供下式B所示的化合物：
Figure PCTCN2018072766-appb-000024
式中，R为H或卤素。
在一个或多个实施方案中，式B化合物选自化合物a和化合物b，即：
Figure PCTCN2018072766-appb-000025
本文还提供下式C所示的化合物：
乳糖酸残基-XAN-PABC’    (式C)
式中，
X为极性和非极性不带电荷的氨基酸，如丙氨酸、缬氨酸或苏氨酸；
A为丙氨酸；
N为天冬酰胺；
PABC’为-NH-苯基-CH 2-OH。
在一个或多个实施方案中，乳糖酸残基与X以酰胺键(-C(O)-NH-)相连。
在一个或多个实施方案中，X与A以酰胺键相连。
在一个或多个实施方案中，式C具有下式C-1所示结构：
Figure PCTCN2018072766-appb-000026
本文还提供式C化合物在提高抗癌药物的抗癌活性中的应用。
附图说明
图1：分子定点靶向导致高激活和高效的分子受体在肿瘤细胞表面分布相同。荧光共聚焦显微镜检测对应抗体标记的MDA-MB435肿瘤细胞，天冬氨酸肽链内切酶(左1，绿色)，唾液酸糖蛋白受体(左2，红色)，细胞核染色用DAPI(蓝色)，两图合并共同分布为黄色(左3)。
图2：与Succinyl-AANL-DOX相比，S3静脉注射后具有更多的肿瘤组织分布和渗透。
图3：S1、索拉菲尼和化合物a对Heg2肿瘤细胞的毒性效应。
图4：分子定点靶向导致高激活和高效化合物S1、S2、S3和C11相对于索拉菲尼的肿瘤组织分布。
图5：肿瘤治疗中分子定点靶向导致高激活和高效化合物S1、S2、S3、S4、S5、S6、索拉菲尼和阿霉素的肿瘤大小变化曲线。
图6：通过细胞分化骨髓细胞为M1、M2型巨噬细胞，天冬酰胺肽链内切酶在M2型上高表达和分泌。左图显示为肿瘤诱导的M2巨噬细胞，右图显示M1-炎症型巨噬细胞。亮点(绿色荧光)为天冬酰胺肽链内切酶的染色。
图7：药物对M2肿瘤相关巨噬细胞的毒性比较。
图8：本文化合物的作用机制示意图。
具体实施方式
本文发现，唾液酸糖蛋白受体与天冬氨酸肽链内切酶分子受体在肿瘤细胞表面具有共分布的特点，双靶点的同分布可能是定点靶向导致高激活化合物高效激活的原因；可利用这种共分布的特点设计药物，使其在共分布位置积累和滞留，从而提高其对肿瘤细胞的识别和激活效率。基于这一发现，本发明人通过将特定的天冬酰胺肽链内切酶(Legumain)酶切底物肽与不同种类的糖类进行连接，并测试该连接体的稳定性和酶切效率，筛选到具有预测之外的强激活效果和稳定性相对高的连接体。进一步地，本发 明人利用所筛选得到的连接体连接不同的药物分子，从而获得本公开式A所示的化合物。这些化合物是分子定点靶向导致高激活和高效的化合物，其作用机制如图8所示：本公开的分子定点靶向导致高激活和高效化合物既有被同分布双靶点高效激活以杀死癌细胞的特性，同时也具有通过内吞激活抑制M2型肿瘤相关巨噬细胞、而后激活抗肿瘤免疫的特点，最终产生具有治愈肿瘤，产生机体免疫力，导致肿瘤不再复发的活性。
因此，本公开首先提供式C所示的化合物：
乳糖酸残基-XAN-PABC’   (式C)
式中，X为极性和非极性不带电荷的氨基酸，如丙氨酸、缬氨酸或苏氨酸；A为丙氨酸；N为天冬酰胺；PABC’为-NH-苯基-CH 2-OH。
式C以及含有本文式C结构的其它化合物中，乳糖酸残基(Lacto)、X和N酰胺键相连，而PABC’也通过酰胺键与天冬酰胺残基(N)相连。
应理解的是，作为基团的“-NH-”中的“N”指氮原子，而作为氨基酸残基的“N”则指天冬酰胺。此外，本文中，酰胺键指“-C(O)-NH-”。
在某些实施方案中，式C具有下式C-1所示结构：
Figure PCTCN2018072766-appb-000027
式C化合物可作为本公开分子定点靶向导致高激活和高效化合物中的连接体部分，用于与活性药物分子进行连接。具体而言，本发明的分子定点靶向导致高激活和高效化合物具有下式A所示的结构：
乳糖酸残基-XAN-PABC-Z   (式A)
式中，X为极性和非极性不带电荷的氨基酸，如丙氨酸、缬氨酸或苏氨酸；A为丙氨酸；N为天冬酰胺；PABC为-NH-苯基-CH 2-O-；Z为感兴趣的药物分子。
通常，乳糖酸残基、XAN和PABC均通过酰胺键相互连接，而PABC与Z以酯基(-O-C(O)-)相连。
在某些实施方案中，式A化合物的结构进一步如本文所公开的式I所示。
感兴趣的药物分子Z可选自下式B所示的索拉菲尼衍生物：
Figure PCTCN2018072766-appb-000028
式中，R为H或卤素。
本文中，“卤素”包括F、Cl、Br和I。
在某些实施方案中，式B化合物选自本文所公开的化合物a和化合物b。
感兴趣的药物分子Z还可以是，例如阿霉素、达拉非尼、多韦替尼和莫特塞尼。
可根据感兴趣药物分子的药效结构确定与PABC连接的位点。通常是在远离其活性位点的位置上与PABC连接。连接的方式可以是各种合适的方式。本文中，药物分子与PABC通过酯基，即-O-C(O)-相连。
在本公开的某些实施方案中，X为丙氨酸、缬氨酸或苏氨酸，因此式A可以是乳糖酸残基-AAN-PABC-Z、乳糖酸残基-VAN-PABC-Z或乳糖酸残基-TAN-PABC-Z。
在本公开的某些实施方案中，X为丙氨酸，因此，本文式I化合物的结构可如式II所示。在其它实施方案中，X为缬氨酸，因此，本文式I化合物的结构可如式III所示。在其它实施方案中，X为苏氨酸，因此本文式I化合物的结构可如式IV所示。
示范性的本文式A或式I化合物可如前文所述的S1-S18所示。
本文也包括本文式A或式I化合物的药学上可接受的盐。药学上可接受的盐的例子包括但不限于无机酸盐和有机酸盐，例如盐酸盐、氢溴酸盐、磷酸盐、硫酸盐、柠檬酸盐、乳酸盐、酒石酸盐、马来酸盐、富马酸盐、甲磺酸盐、扁桃酸盐和草酸盐；以及与碱例如钠羟基、三(羟基甲基)胺基甲烷(TRIS，胺丁三醇)和N-甲基葡糖胺形成的无机碱盐和有机碱盐。例如，在某些实施方案中，式A中的药物分子Z为达拉非尼、式B化合物的甲磺酸盐，或者为多韦替尼的羟基丙酸盐等。
本文也包括式A或式I化合物的立体异构体，也包括立体异构体的外消旋体。可以根据本领域技术人员众所周知的方法分离出单独的对映体。但应理解的是，本文所述的化合物中，乳糖酸以及X、A和N优选为其天然存在的异构体形式。
本文部分化合物的制备流程可如本文实施例1－3所示。例如，可先行合成式A化合物中的XAN-PABC-Z部分，然后在于乳糖酸相连；或者，可先行合成式A化合物中的乳糖酸残基-XAN-PABC部分，然后在于感兴趣的药物分子Z相连。
因此，本文提供一种药物组合物，该药物组合物含有式A化合物或其药学上可接受的盐和药学上可接受的载体。
药学上可接受的载体通常是安全、无毒的，且广义上可包括制药产业中用于制备 药物组合物的任何已知物质，如填充剂、稀释剂、凝结剂、黏合剂、润滑剂、助流剂、稳定剂、着色剂、润湿剂、崩解剂等。合适的药学上可接受的载体包括糖类，如乳糖或蔗糖、甘露醇或山梨醇；纤维素制剂和/或钙磷酸盐，例如磷酸三钙或磷酸氢钙；淀粉糊，包括玉米淀粉、小麦淀粉、大米淀粉、马铃薯淀粉、明胶、黄芪胶、甲基纤维素、羟丙基甲基纤维素、羧甲基纤维素钠和/或聚乙烯吡咯烷酮；硅石、滑石、硬脂酸或其盐，如硬脂酸镁或硬脂酸钙和/或聚乙二醇；等等。在选择药学上可接受的载体时，主要需考虑此药物组合物的给药方式，这为本领域技术人员所熟知。
药物组合物中可含有治疗有效量的式A化合物或其药学上可接受的盐。“有效量”指某成分的用量足以产生所期望的反应。具体的有效量取决于多种因素，诸如欲治疗的特定病症、患者的身体条件(如患者体重、年龄或性别)、治疗持续时间、共同施与的疗法(如果有的话)以及所用的具体配方。“有效量”也指在该用量下，本申请多肽的毒性或负面效果不及于其所带来的正面疗效。在本公开中，式A化合物或其药学上可接受的盐的治疗有效量可与常规的药物分子Z的治疗有效量相当。在某些情况下，由于偶联了本公开的连接体(即式C化合物)，具有更高的激活效率和抗肿瘤效果，因此，本公开式A化合物或其药学上可接受的盐的治疗有效量低于常规的药物分子Z的治疗有效量。
可根据已知的药学程序来制备上述药物组合物，譬如《雷明顿制药科学》(Remington’s Pharmaceutical Sciences)(第17版，Alfonoso R.Gennaro编，麦克出版公司(Mack Publishing Company)，伊斯顿，宾夕法尼亚(1985))一书中有详细的记载。
本公开的药物组合物可以是各种合适的剂型，包括但不限于药片、胶囊、注射剂等，并可通过任何合适的途径给药，以达到其预期目的。例如，可以通过肠外、皮下、静脉、肌肉、腹腔内、透皮、口腔、鞘内、颅内、鼻腔或外用途径给药。药的剂量可根据病人的年龄、健康与体重、并行治疗的种类和治疗的频率等来决定。
本公开的药物组合物可以给予任何哺乳动物，尤其是人。
本文式A化合物或其药学上可接受的盐或药物组合物尤其可用于治疗癌症或癌细胞转移。可采用本文式A化合物或其药学上可接受的盐或药物组合物治疗的癌症可根据感兴趣的药物分子Z本身所具有的治疗活性而定。例如，本领域已知，索拉菲尼是多靶向性肿瘤治疗药物，其适应症包括但不限于无法手术或远处转移的肝肿瘤细胞、不能手术的肾肿瘤细胞和对放射性碘治疗不再有效的局部复发或转移性、逐步分化型甲状腺患者等。阿霉素抗瘤谱较广，适用于急性白血病(淋巴细胞性和粒细胞性)、恶性淋巴瘤、乳腺癌、支气管肺癌(未分化小细胞性和非小细胞性)、卵巢癌、软组 织肉瘤、成骨肉瘤、横纹肌肉瘤、尤文肉瘤、肾母细胞瘤、神经母细胞瘤、膀胱癌、甲状腺癌、前列腺癌、头颈部鳞癌、睾丸癌、胃癌和肝癌等。
因此，本文式A化合物或其药学上可接受的盐或药物组合物可用于治疗的癌症包括但不限于肝癌、肾癌、甲状腺癌、结肠直肠癌、膀胱癌、脑癌、乳腺癌、宫颈癌、直肠癌、食管癌、肺癌(例如支气管肺癌，包括未分化小细胞性和非小细胞性)、鼻咽癌、胰腺癌、前列腺癌、皮肤癌、胃癌、子宫癌、卵巢癌、睾丸癌、血癌(例如慢性或急性白血病，包括淋巴细胞性和粒细胞性白血病)、恶性淋巴瘤、纤维素肉瘤、软组织肉瘤、成骨肉瘤、横纹肌肉瘤、尤文肉瘤、肾母细胞瘤、神经母细胞瘤、甲状腺癌和头颈部鳞癌。本文的式A化合物或其药学上可接受的盐或药物组合物也可用于治疗这些伴随这些癌症发生的癌细胞转移。
在某些方面，本公开式A化合物或其药学上可接受的盐或药物组合物还可刺激T细胞的繁殖和对病灶的侵入、抑制肿瘤相关巨噬细胞和/或促进刺激免疫反应。
因此，本公开提供一种治疗癌症或癌细胞转移的方法，所述方法包括给予有此需要的对象治疗有效量的本文所公开的式A化合物或其药学上可接受的盐或药物组合物。所述癌症或癌细胞转移如前文所述。
在某些方面，本公开还提供一种刺激T细胞的繁殖和对病灶的侵入、抑制肿瘤相关巨噬细胞和/或促进刺激免疫反应的方法，所述方法包括给予有此需要的对象治疗有效量的本文所公开的式A化合物或其药学上可接受的盐或药物组合物。
感兴趣的“对象”可以是任何哺乳动物，尤其是人。
还提供的是本公开式A化合物或其药学上可接受的盐在制备治疗癌症或癌细胞转移用的药物中的应用，或在制备免疫治疗药物中的应用。所述癌症或癌细胞转移如前文所述；所述免疫治疗药物可用于刺激T细胞的繁殖和对病灶的侵入、抑制肿瘤相关巨噬细胞和/或促进刺激免疫反应。
还提供的是本公开的式A化合物或其药学上可接受的盐，用于治疗癌症或癌细胞转移，或用于刺激T细胞的繁殖和对病灶的侵入、抑制肿瘤相关巨噬细胞和/或促进刺激免疫反应。
应理解的是，本文所述各方面、各实施方案以及下述各具体实施例中的各特征可任意组合，构成优选的实施方案。因此，例如，虽然上述公开仅体积式A化合物或其药学上可接受的盐，但本文所公开的任一落入式A范围内的具体化合物，例如式I、II、III和IV化合物，或化合物S1-S18均可用于上述具体公开的任意一种癌症或癌细胞转移的治疗。
下面结合具体实施例，进一步阐述本申请。除非另外说明，下述实施例将使用本领域技术人员已知的化学、生物化学和免疫学的常规方法。这些技术在文献中有完整的解释。此外，实施例中所用到的各种材料和试剂，除非另有说明，否则均为已知的和/或常规的材料和试剂。
实施例1：化合物S1、S7和S13的合成
采用以下流程合成化合物S1、S7和S13，其中，X为丙氨酸：
Figure PCTCN2018072766-appb-000029
QHL001的合成
在100ml的单口瓶中，依次加入DMF(40ml)，对氨基苯酚(5g，45.8mmol)，叔丁醇钾(5.35g，47.7mmol)。搅拌30分钟后，加入4-氯吡啶-2-羧酸叔丁酯(11.75g，55mmol)。室温搅拌5分钟后，升温至80℃，反应过夜。减压蒸除DMF，残留物用二氯甲烷溶解，水洗，萃取，分液。有机相干燥，旋干，硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝80：1～10：1)，得到白色固体QHL001(7.86g，收率： 60％)。
QHL002的合成
在100ml的单口瓶中，依次加入DCM(30ml)，QHL001(7.80g，27.3mmol)，搅拌5分钟后，用冰盐浴将体系降温至0℃，分批加入4-氯-3-三氟甲基异氰酸苯酯(7.0g，32.8mmol)。加完后，撤去冰盐浴，升至室温，反应过夜。加入50ml水，萃取，分液。有机相干燥，旋干，硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～10：1)，得到棕色固体QHL002(10.54g，收率76％)。
QHL003的合成
在100ml的单口瓶中，依次加入DCM(15ml)，三氟醋酸(15ml)，QHL002(10.5g，20.7mmol)，三乙基硅烷(2.5ml)，室温搅拌至QHL002完全反应。反应结束后，将反应液旋干，粗品用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～5：1)，得到白色固体QHL003(7.47g，收率80％)。
QHL004的合成
在50ml的单口瓶中，依次加入DMF(10ml)，QHL003(417mg，0.92m mol)，N-BOC-N-甲基乙二胺(200mg，1.25mmol)，HATU(420mg，1.10mmol)。搅拌5分钟后，滴入DIPEA(0.5ml，2.76mmol)。室温搅拌至QHL003完全反应。减压蒸除DMF，粗产品用乙酸乙酯溶解，水洗1次。有机相干燥，旋干，硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～20：1)，得到淡黄色固体QHL004(454mg，收率83％)。
QHL005的合成
将化合物QHL004(450mg，0.764mmol)溶于DCM(10ml)中，加入三氟乙酸(10ml)。室温下搅拌至QHL004完全反应。蒸除溶剂，残留固体用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝30：1～10：1)，得到淡黄色固体QHL005(340mg，，收率：90％)。
QHL006的合成
在100ml单口瓶中，依次加入L-Ala-L-Ala-L-Asn(Trt)-PABC(6.21g，10mmol)，DMF(20ml)，DIPEA(1.29g，10mmol)。室温搅拌5分钟后，冰盐浴将体系降温 至0℃。缓慢加入氯甲酸烯丙酯(1.21g，10mmol).室温搅拌过夜。反应结束后，减压蒸馏除去DMF，残留物经硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～10：1)，得到白色固体QHL006(5.0g，收率71％)。
QHL007的合成
在100ml单口瓶中，依次加入DCM(15ml)，三氟乙酸(15ml)，QHL006(5.0g)，室温搅拌至QHL012反应完全。然后旋蒸除去DCM和三氟乙酸，残留物用甲基叔丁基醚打浆1h。过滤，收集固体。再将固体溶于甲醇(30ml)中，加入DIPEA(15ml)，室温搅拌2h后，旋干溶剂，得到粗品。粗品再次用甲基叔丁基醚打浆1h，过滤，干燥，得到QHL007(2.75g，收率92％)。
QHL008的合成
在100ml单口瓶中，依次加入DMF(15ml)，QHL007(2.75g，5.94mmol)，4，4-二硝基碳酸二苯酯(3.54g，11.6mmol)，DIPEA(1.13g，8.76mmol)，室温搅拌至QHL007反应完全。反应结束后，减压蒸馏除去DMF，残留物经硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～10：1)，得到白色固体QHL008(2.43g，收率65％)。
QHL009的合成
在50ml的单口瓶中，依次加入DMF(10ml)，QHL005(508mg，1mmol)，QHL008(629mg，1mmol)。搅拌5分钟后，滴入DIPEA(387mg，3mmol)，继续室温搅拌2h。减压蒸除DMF，粗产品用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～10：1)，得到白色固体QHL009(698mg，收率：70％)。
QHL010的合成
在50ml的单口瓶中，依次加入DMF(10ml)，QHL009(310mg，0.31mmol)，乙酸(274mg，4.65mmol)，三苯基膦钯(72mg，0.062mmol)，三正丁基氢化锡(1.17g，4.03mmol)，置换氮气后，室温搅拌至QHL009反应完全。反应结束后，减压蒸除DMF，粗产品用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～10：1)，得到白色固体QHL010(175mg，收率：62％)。
S1(Lacto-AAN-PABC-化合物a)的合成
将乳糖酸(3.8g，10mmol)溶于无水甲醇(100ml)中，升温至回流，反应24小时后，冷却至室温。将QHL010(175mg，0.192mmol)溶解于无水甲醇(10ml)中，室温滴加至上述乳糖酸的甲醇溶液中。滴加完毕后，将体系升温至60℃，反应过夜。减压蒸干溶剂，粗品用反相制备纯化，得到白色固体即化合物S1(91mg，收率36％)。
采用与S1合成类似的方法，用不同的氨基酸残基进行连接，制备得到化合物S7(Lacto-VAN-PABC-化合物a)和S13(Lacto-TAN-PABC-化合物a)。
实施例2：化合物S2、S8和S14的合成
采用以下流程合成化合物S2、S8和S14，其中X为丙氨酸：
Figure PCTCN2018072766-appb-000030
QHL012的合成
在100ml的单口瓶中，依次加入DMF(40ml)，4-氨基-3-氟-苯酚(5.8g，45.8mmol)，叔丁醇钾(5.35g，47.7mmol)。搅拌30分钟后，加入4-氯吡啶-2-羧酸叔丁酯(11.75g， 55mmol)。室温搅拌5分钟后，升温至80℃，反应过夜。减压蒸除DMF，残留物用二氯甲烷溶解，水洗，萃取，分液。有机相干燥，旋干，硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝80：1～10：1)，得到白色固体QHL012(9.7g，收率：70％)。
QHL013的合成
在100ml的单口瓶中，依次加入DCM(30ml)，QHL012(8.30g，27.3mmol)，搅拌5分钟后，用冰盐浴将体系降温至0℃，分批加入4-氯-3-三氟甲基异氰酸苯酯(7.0g，32.8mmol)。加完后，撤去冰盐浴，升至室温，反应过夜。加入50ml水，萃取，分液。有机相干燥，旋干，硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～10：1)，得到棕色固体QHL013(11.2g，收率75％)。
QHL014的合成
在100ml的单口瓶中，依次加入DCM(15ml)，三氟醋酸(15ml)，QHL013(11.2g，20.7mmol)，三乙基硅烷(2.5ml)，室温搅拌至QHL013完全反应。反应结束后，将反应液旋干，粗品用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～5：1)，得到白色固体QHL014(7.92g，收率80％)。
QHL015的合成
在50ml的单口瓶中，依次加入DMF(20ml)，QHL014(4.42g，9.2mmol)，N-BOC-N-甲基乙二胺(2.00g，12.5mmol)，HATU(4.20g，11mmol)。搅拌5分钟后，滴入DIPEA(5ml，27.6mmol)。室温搅拌至QHL014完全反应。减压蒸除DMF，粗产品用乙酸乙酯溶解，水洗1次。有机相干燥，旋干，硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～20：1)，得到淡黄色固体QHL015(4.81g，收率80％)。
QHL016的合成
将化合物QHL015(4.80g，7.64mmol)溶于DCM(10ml)中，加入三氟乙酸(10ml)。室温下搅拌至QHL015完全反应。蒸除溶剂，残留固体用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝30：1～10：1)，得到淡黄色固体QHL016(3.60g，收率：90％)。
QHL017的合成
在50ml的单口瓶中，依次加入DMF(10ml)，QHL016(670mg，1.28mmol)，QHL008(965mg，1.54mmol)。搅拌5分钟后，滴入DIPEA(1.4ml，7.68mmol)，置换氮气后，继续室温搅拌3h。减压蒸除DMF，粗产品用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～15：1)，得到白色固体QHL017(1.0g，收率：77％)。
QHL018的合成
在50ml的单口瓶中，依次加入DMF(10ml)，QHL017(500mg，0.49mmol)，乙酸(0.42ml，7.39mmol)，三苯基膦钯(116mg，0.10mmol)，三正丁基氢化锡(1.75ml，6.37mmol)，置换氮气后，室温搅拌至QHL017反应完全。反应结束后，减压蒸除DMF，粗产品用硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝50：1～10：1)，得到白色固体QHL018(300mg，收率：65％)。
S2的合成
将乳糖酸(3.8g，10mmol)溶于无水甲醇(100ml)中，升温至回流，反应24小时后，冷至室温。将QHL018(175mg，0.188mmol)溶解于无水甲醇(10ml)中，室温滴加至上述乳糖酸的甲醇溶液中。滴加完毕后，将体系升温至60℃，反应过夜。减压蒸干溶剂，粗品用反相制备纯化，得到白色固体，即S2(102mg，收率42％)。
采用与S2合成类似的方法，用不同的氨基酸残基进行连接，制备得到化合物S8(Lacto-VAN-PABC-化合物b)和S14(Lacto-TAN-PABC-化合物b)。
实施例3：化合物S3-S6、S9-S11和S15-S18的合成
采用以下流程合成化合物S3-S6、S9-S11和S15-S18，通式中，X为丙氨酸、苏氨酸或缬氨酸。
Figure PCTCN2018072766-appb-000031
具体而言，先以XAN-PABC中X的氨基端与乳糖酸的羧基进行反应，生成定点靶向连接体(Lacto-XAN-PABC)。然后对Lacto-XAN-PABC进行活化，生成Lacto-XAN-PABC-PNP。化合物Z以其结构上含有的氨基对Lacto-XAN-PABC-PNP进行亲核反应，即得到化合物Lacto-XAN-PABC-Z。
以下以化合物S3为例阐述这些化合物的合成：
Figure PCTCN2018072766-appb-000032
QHL020的合成
将乳糖酸(3.8g,10mmol)溶于无水甲醇(100ml)中,升温至回流，反应24小时后，冷至室温。将L-Ala-L-Ala-L-Asn-PABC(760mg,2.0mmol)溶解于无水甲醇(10ml)中，室温滴加至上述乳糖酸的甲醇溶液中。滴加完毕后，将体系升温至60℃，反应过夜。减压蒸干溶剂，粗品用反相制备纯化，得到白色固体QHL020(650mg，收率 45％)。
QHL021的合成
在100ml单口瓶中，依次加入DMF(15ml)，QHL020(650mg，0.90mmol)，4,4-二硝基碳酸二苯酯(354mg,1.16mmol)，DIPEA(113mg,0.88mmol)，室温搅拌过夜。反应结束后，减压蒸馏除去DMF，残留物经硅胶柱层析分离纯化(按体积比计，二氯甲烷：甲醇＝25:1～3:1)，得到白色固体QHL021(243mg，收率30％)。
S3的合成
在50ml的单口瓶中,依次加入DMF(10ml),QHL021(180mg,0.2mmol),盐酸阿霉素(192mg,0.33mmol)。搅拌5分钟后，滴入DIPEA(194mg,1.5mmol)，继续室温搅拌5h。减压蒸除DMF，粗产品用反相制备纯化，得到QHL022红色固体(127mg，收率：49％)即化合物S3。
当Z为阿霉素时，改变连接的氨基酸，分别得到实施例S9，S15；
当Z为达拉非尼时，改变连接的氨基酸，分别得到实施例S4，S10，S16；
当Z为多韦替尼时，改变连接的氨基酸，分别得到实施例S5，S11，S17；
当Z为莫特塞尼时，改变连接的氨基酸，分别得到实施例S6，S12，S18。
质谱(MS)检测结果确认S1-S18化合物，分子量依次如下表1所示，与结构计算预测的分子量相一致。
表1
编号 质谱检测 分子量 性状 产量(毫克) 收率
S1 1253 1253.18 白色固体 91 36％
S2 1272 1271.57 白色固体 102 42％
S3 1289 1289.20 红色固体 127 49％
S4 1263 1263.23 白色固体 102 40％
S5 1135 1135.09 白色固体 114 49％
S6 1117 1117.12 白色固体 70 31％
S7 1282 1281.63 白色固体 103 40％
S8 1300 1299.62 白色固体 110 45％
S9 1317 1317.26 红色固体 114 43％
S10 1291 1291.29 白色固体 117 45％
S11 1163 1163.14 白色固体 96 41％
S12 1145 1145.17 白色固体 65 28％
S13 1284 1283.60 白色固体 85 30％
S14 1302 1301.59 白色固体 92 37％
S15 1319 1319.23 红色固体 108 41％
S16 1293 1293.26 白色固体 97 37％
S17 1165 1165.12 白色固体 101 43％
S18 1147 1147.15 白色固体 56 25％
实施例4：分子定点靶向导致高激活连接体组分合成筛选
肿瘤组织特异性的激活位点是短肽，因为天冬氨酸肽链内切酶的酶活中心位于球囊状内陷的底部，切割位点需要接近酶活中心，这时化合物对切割位点是否有空间位阻变为非常重要。
通过特定的天冬酰胺肽链内切酶(Legumain)酶切底物肽与不同种类的糖类进行连接，并测试所得连接体的稳定性和酶切效率，筛选到具有预测之外的强激活效果和稳定性相对高的连接体，结果如下表2所示。
表2
Figure PCTCN2018072766-appb-000033
Figure PCTCN2018072766-appb-000034
上述结果说明：本发明的乳糖酸-AAN-对氨基苯甲醇不但不影响激活效率，与PEG-Ala-Ala-ASN-对氨基苯甲醇相比反而促进了激活效率和稳定性。
实施例5：唾液酸糖蛋白受体与天冬氨酸肽链内切酶的细胞分布特性
本发明人深入研究发现，唾液酸糖蛋白受体与天冬氨酸肽链内切酶分子受体在肿瘤细胞表面具有共分布的特点。具体而言，在MDA-MB435乳腺癌肿瘤细胞的免疫荧光染色中，用荧光共聚焦显微镜检测对应抗体标记的唾液酸糖蛋白受体与天冬氨酸肽链内切酶，细胞核染色用DAPI。结果如图1所示，显示唾液酸糖蛋白受体和天冬氨酸肽链内切酶的位点分布相同。这种共分布的特点可以使本发明化合物在共分布位置积累和滞留，从而提高其对肿瘤细胞的识别和激活效率。
实施例6：本发明化合物的的组织分布特性
由于DOX、Succinyl(丁二酰)-AANL-DOX和S3具有自发荧光，因此可用荧光显微镜检测肿瘤组织中它们的分布情况。静脉注射10umol/kg的DOX、Succinyl-AANL-DOX和S3。12小时后检测肿瘤组织切片的药物分布图像和肿瘤组织匀浆荧光强度。细胞核染色用DAPI。结果如图2所示。结果显示，与Succinyl-AANL-DOX相比，S3静脉注射后具有更多的肿瘤组织分布和渗透，说明S3所具有的分子定点靶向功能使其能够同时双靶向于唾液酸糖蛋白受体与天冬氨酸肽链内切酶，从而比Succinyl-AANL-DOX具有很强的肿瘤部位的滞留效应。
实施例7：索拉菲尼衍生物的合成
索拉菲尼不具备与本发明式II化合物偶联的可能性。为了解决这一困境，本文对索拉菲尼分子中的吡啶环邻位的甲酰胺基团进行了变构合成和筛选，得到既满足构效关系，又能增加释放药效的特殊化合物(即化合物a和化合物b)。对化合物a和化合物b进行了稳定性及细胞活性实验，结果表明化合物a和化合物b在弱酸、弱碱及中性缓冲体系中稳定性良好，不会发生降解，并且对癌细胞的抑制效果均优于阳性对照 药索拉菲尼及瑞戈非尼(图3)。
Figure PCTCN2018072766-appb-000035
实施例8：S1和化合物a的抗肿瘤细胞毒性
收集对数期Heg2细胞，调整细胞悬液浓度，每孔加入140ul，铺板使待测细胞调密度～5000个/孔；5％CO 2，37℃孵育过夜，至细胞单层铺满孔底(96孔平底板)，再加入连续浓度梯度的给予不同浓度的化合物S1、化合物a和索拉菲尼，药物设置9个浓度梯度，每孔10ul，设3个复孔；5％CO 2，37℃PH6.5孵育48小时，倒置显微镜下观察；每孔加入20ulMTT溶液(5mg/ml，即0.5％MTT)，继续培养4h。终止培养，小心吸去孔内培养液；每孔加入100ul二甲基亚砜，置摇床上低速振荡10min，使结晶物充分溶解。在酶联免疫检测仪OD490nm处测量各孔的吸光值。同时设置调零孔(培养基、MTT、二甲基亚砜)，对照组(细胞、相同浓度的药物溶解介质、培养基、MTT、二甲基亚砜)。检测后对化合物对正常肝细胞的毒性进行分析，结果见图3。图3显示给予不同浓度的化合物2天后，化合物a相对索拉菲尼具有更高的毒性。而S1通过偶联连接体变为一个对正常细胞无毒性的药物。
实施例9：化合物的相对激活特性
将样品化合物和部分对照化合物(本文中，所有对照化合物可采用类似于实施例1－3所述的方法进行合成)统一用酶切溶液稀释10倍到1毫克/毫升。在本实验中，在37℃、2小时条件下在天冬氨酸肽链内切酶(1umol/L，pH6.0)中加入1毫克/毫升的样品化合物，反应后酶能够导致释放出酶切产物，通过HPLC检测化合物的减少和产物的增加，从而比较酶激活效率〔指被酶剪切而释放出来的产物产生相对于原化合物比率〕。结果如下表3所示。
表3：本发明化合物和部分对照化合物的激活效率
化合物 激活效率(％)
C1：AANL-化合物a 1.8(不激活)
C2：AAN-PABC-化合物a 46.7
C3：PEG-AAN-PABC-化合物a 51.4
C4：葡萄糖-AAN-PABC-化合物a 46.7
C5：Lacto-AAN-PABC-紫杉醇 59.3
S3：Lacto-AAN-PABC-阿霉素 82.6
S1：Lacto-AAN-PABC-化合物a 86.7
S7：Lacto-VAN-PABC-化合物a 90.5
S13：Lacto-TAN-PABC-化合物a 98.6
C6：AANL-化合物b 1.6(不激活)
C7：AAN-PABC-化合物b 38.4
C8：PEG-AAN-PABC-化合物b 51.4
C9：葡萄糖-l-PEG-AAN-PABC-化合物b 16.7
S2：Lacto-AAN-PABC-化合物b 88.4
S8：Lacto-VAN-PABC-化合物b 93.7
S14：Lacto-VAN-PABC-化合物b 99.5
C10：Lacto-LAN-PABC-化合物b 2.7
C11：EMC-AANL-阿霉素 54.5
上述结果说明：天冬酰胺肽链内切酶对底物肽和底物肽两端的基团有结构要求，药物与不同的连接体连接对药物激活具有不同的影响：C1，C6不被激活说明，AANL连接体对化合物a，b激活无效。C2，C3，C4，C7，C8，C9激活效率比S1，S2低很多，说明与不存在Lacto相比或与PEG和Succinyl相比Lacto具有特殊构效关系，促进了整体化合物的激活。S1比C5相比，具有更高的激活效率，说明化合物a，b比紫杉醇更适用于Lacto-AAN-PABC-连接体。S1，S7，S13激活效率依次提高，而C10等其他氨基酸替代无激活，说明氨基酸筛选优化的连接体对整体药物激活具有优化的重要作用。S3与C11相比激活效率提高，说明与本发明的连接体能提高药物的激活效率。
实施例10：化合物对成药性评价中的关键数据(固体稳定性)的影响
在60℃避光放置10天，进行稳定性检测。通过HPLC检测化合物的含量变化与时间0时的化合物比例，计为稳定性数值(％)。结果如下表4所示。
表4
化合物 稳定性(％)
C1：AANL-化合物a 96.8，稳定
C2：AAN-PABC-化合物a 89.4，不稳定
C3：PEG-AAN-PABC-化合物a 87.2，不稳定
C4：葡萄糖-AAN-PABC-化合物a 85.7，不稳定
C5：Lacto-AAN-PABC-紫杉醇 89.3，不稳定
S3：Lacto-AAN-PABC-阿霉素 99.8，稳定
S1：Lacto-AAN-PABC-化合物a 96.7，稳定
S7：Lacto-VAN-PABC-化合物a 97.2，稳定
S13：Lacto-TAN-PABC-化合物a 98.6，稳定
C6：AANL-化合物b 91.6，稳定
C7：AAN-PABC-化合物b 85.6，不稳定
C8：PEG-AAN-PABC-化合物b 86.5，不稳定
C9：葡萄糖-AAN-PABC-化合物b 90.7，稳定
S2：Lacto-AAN-PABC-化合物b 99.6，稳定
S8：Lacto-VAN-PABC-化合物b 98.4，稳定
S14：Lacto-VAN-PABC-化合物b 97.8，稳定
C10：Lacto-LAN-PABC-化合物b 92.2，稳定
C11：EMC-AANL-阿霉素 96.5，稳定
上述结果说明：本公开通过将药物分子与本公开的连接体进行连接，大大提高了药物的稳定性。
实施例11：本文化合物相对于索拉菲尼和其他连接方式的药物的代谢分布
通过静脉注射10微摩每公斤剂量的药物到荷瘤小鼠中，手术获取肿瘤组织匀浆，通过HPCL方法并检测药物含量。结果如图4所示，证明化合物S1和S2相比索拉菲尼在肿瘤中的分布成倍提高，化合物S3相比C11也具有提高在肿瘤中分布的特性。
实施例12：本文化合物相对于索拉菲尼和其他连接方式的毒理
试验目的：通过测定小鼠静脉用药MTD(最大耐受剂量)实验，了解本发明分 子定点靶向导致高激活化合物的急性毒性。
试验药物：试验药物如下表3所示，各药物的注射液和对照药物使用注射用水统一溶解，试验时用生理盐水稀释到相应剂量。
动物：一级巴比赛(BALB/C)小鼠(购自上海史莱克生物科技有限公司)，体重19-21g，雌性。
方法和结果：受试BALB/C小鼠36只，体重19-21g，雌性，按体重随机分组，每组10只。如表3所示，按表3中不同剂量药物溶于生理盐水中，静脉注射，并纪录出现死亡时剂量和获得最大耐受剂量(MTD)。并进行生理盐水组、阿霉素组注射液(市售，北京悦康)的对照试验，每个小鼠给药体积0.2ml。连续观察17天，每日观察动物是否出现立毛树立、糟乱无光泽、昏睡、弯腰驼背、过激反应等，记录体重和死亡情况。在第3、5、14天采血样进行全血球计数，在第14天解剖动物采取心脏、肝脏、肾脏、肺、脾脏、胰腺HE染色观察。死亡率结果如下表5所示。
表5：受试小鼠分别接受不同剂量的S1，S2，S3，S4，S5和S6注射液以及生理盐水、阿霉素注射液的死亡率结果
组别 出现死亡剂量(mg/kg) MTD(mg/kg) 死亡数(只)
生理盐水 等体积   0
S1 350 300 1
S2 350 300 2
S3 110 100 1
S4 300 280 2
S5 320 310 2
S6 290 280 1
S7 345 300 1
S8 340 280 2
S9 120 100 2
S10 320 310 1
S11 330 300 2
S12 300 290 1
S13 360 320 2
S14 350 310 1
S15 100 90 1
S16 300 290 2
S17 310 290 1
S18 290 280 2
阿霉素 10 8 3
索拉菲尼 12 11 0
C1：AANL-化合物a 80 65 1
C2：AAN-PABC-化合物a 70 60 2
C3：PEG-AAN-PABC-化合物a 80 60 1
C4：葡萄糖-AAN-PABC-化合物a 90 80 2
C11：EMC-AANL-阿霉素 120 110 2
实施例13：本文化合物相对于索拉菲尼和其他连接方式的药效
在人肝癌HepG2移植瘤模型中给予等摩尔(30umol/kg)的各药物(S1-S6、阿霉素和索拉菲尼，对照组给予生理盐水)，在不同时间点测试给药后肿瘤体积大小。结果如图5所示，与阳性对照药(阿霉素和索拉菲尼)相比，化合物S1-S6给药组对肿瘤的治疗能力大大提高。这和药物设计理念中的靶向机制有关，药物在肿瘤微环境中的双靶向局部释放，因此对肿瘤的治疗能力远远优于阳性对照药。同时，S1-S6在肿瘤局部靶向释放，迅速减小荷瘤鼠的肿瘤体积，并在给药两次后，出现肿瘤消失现象。随着给药次数的增加，S1-S6给药组的荷瘤鼠均被治愈，并在停药后，没有出现肿瘤重新生长的现象。
实施例14：本文化合物相对于索拉菲尼等对照组的免疫治疗
(1)将来源于美国模式培养物集存库ATCC的D121肺癌细胞培养于含10％胎牛血清的DMEM培养基中，细胞按照常规使用含有EDTA胰蛋白酶消化，每周传代两到三次，放置于37℃，5％的CO 2培养箱中培养。
(2)动物：C57 BALB/C小鼠，6-8周龄，雌性，体重约18-22g，购自上海史莱克生物科技有限公司。
(3)免疫：小鼠腹腔注射100μL，数量为5×10 5经反复冻融死亡的D121肺癌细胞，免疫3次，每次间隔2周。
(4)细胞接种：收集对数生长期肿瘤细胞，用DMEM基础培养基调整D121细胞浓度为(1×10 7/ml)，用1ml注射器将0.1ml细胞悬液接种于每只小鼠右侧靠近背部皮下。观察和测量肿瘤体积，平均肿瘤体积在接种后约7天达到100-200mm 3，即对肿瘤细胞荷瘤鼠进行分组和给药。表9中的免疫组就是用D121肺癌细胞免疫，而无D121死肿瘤细胞免疫组注射生理盐水为对照。
(5)治疗过程：i.v.，S1～S8都使用1/6 MTD的剂量，每周一次，共4周。免疫抑制调节点蛋白Anti-Pd L1抗体注射治疗每周两次。共两周。
(6)实验观察：在整个实验过程中，对实验动物的使用和观察均按照AAALAC的规定进行。实验动物在接种肿瘤细胞后，每天进行观察，记录其发病和死亡等。在常规实验过程中，对所有的实验动物进行行为、进食、摄水、体重改变、毛发光泽和其他一些异常情况的监测和记录。
(7)肿瘤CD8+T细胞(T淋巴细胞亚群)分析。肿瘤组织经过研磨，用Cell starainer 40μm Nylon细胞滤网过滤分离出单个肿瘤细胞，用血细胞裂解液裂解两次，每次20min，再用1％BSA-PBS缓冲液洗两次，离心，重悬后进行细胞计数。取1×10 5个细胞用白细胞共同抗原CD45-PE和CD8-FITC标记的抗体在室温避光孵育1小时，然后用流式细胞仪分析白细胞共同抗原(CD45)阳性细胞中T淋巴细胞抗原(CD8)阳性细胞的比例。
(8)分组与结果测量如下表6所示。
表6
Figure PCTCN2018072766-appb-000036
Figure PCTCN2018072766-appb-000037
(9)结果与讨论：根据表9的数据，S1-S6化合物与溶媒和阳性对照组相比均显示出良好的抑瘤作用。而且，通过与Anti-Pd L1抗体联合治疗，都显示出了100％的抑瘤作用，优于单药治疗组，表现出非常好的协同药效。并且，联合治疗具有良好的促进免疫作用。流式细胞术分析结果显示，联合治疗组中的CD8+T细胞比例上升，导致CD8+CD45+细胞数量增多。而对照组不改变免疫治疗的效果，非靶向的阿霉素和索拉菲尼对T细胞有抑制作用。
实施例15：本文化合物相对于索拉菲尼在CT26免疫治疗模型中的新进展
1)CT26肿瘤细胞从美国模式培养物保藏所ATCC购买，细胞使用含有10％胎牛血清DMEM培养液在37℃，5％的二氧化碳条件下培养。每3天传代一次，细胞使用在15代以内。动物：C57小鼠，6-8周龄，全为雌性，购自上海斯莱克实验动物有限公司。
2)肿瘤产生：将10 6个活的CT26肿瘤细胞皮下注射到肿瘤免疫的C57小鼠背部，待肿瘤长至0.3～0.4cm左右时开始治疗，记录计小鼠肿瘤大小(mm 3)，并与溶媒对照组相比计算第42天的抑瘤率。
4)治疗过程：使用IV注射，药物都使用1/3 MTD的剂量，每周一次。免疫抑IV注射治疗每周一次，共6周疗程。
5)统计每组10只中的治愈率，治愈的小鼠和野生组在50天后，再接种2*10 5，检测复发生长情况。
6)分组与结果测量如下表7所示。
表7
Figure PCTCN2018072766-appb-000038
7)结果与讨论：与各对照组相比，S1，S2，S3，S7，S13，S8，S14组都出现了较高的治愈率，即将肿瘤治疗到完全消失。而后再接种CT26肿瘤细胞，野生组能够复发生长肿瘤，而S1，S2，S3，S7，S13，S8，S14治愈组肿瘤不再复发生长，说明老鼠通过药物治疗已经产生对肿瘤细胞的免疫力。S1，S7，S13治愈率提高，说明氨基酸筛选优化的连接体对整体药效具有优化的重要作用。
实施例16：本文化合物构效关系刺激免疫的机制
肿瘤相关巨噬细胞(M2型)是肿瘤生长和复发的帮凶。诱导产生炎症型巨噬细胞(M1型)和肿瘤相关巨噬细胞(M2型)，并用荧光染色证明肿瘤相关巨噬细胞(M2型)高表达天冬酰胺肽链内切酶(图6)。
收集通过M-CSF(10ng/ml)由单核骨髓细胞诱导形成的肿瘤相关巨噬细胞(M2型)，调整细胞悬液浓度，每孔加入140ul，铺板使待测细胞调密度～3000个/孔；5％CO 2，37℃孵育过夜，至细胞单层铺满孔底(96孔平底板)，再加入连续浓度梯度的给予不同浓度的药物，药物设置9个浓度梯度，每孔10ul，设3个复孔；5％CO 2，37℃、pH6.5孵育48小时，倒置显微镜下观察；每孔加入20ul MTT溶液(5mg/ml，即0.5％MTT)，继续培养4h。终止培养，小心吸去孔内培养液；每孔加入100ul二甲基亚砜，置摇床上低速振荡10min，使结晶物充分溶解。在酶联免疫检测仪OD490nm处测量各孔的吸 光值。同时设置调零孔(培养基、MTT、二甲基亚砜)，对照组(细胞、相同浓度的药物溶解介质、培养基、MTT、二甲基亚砜)。检测后对化合物对肿瘤相关巨噬细胞(M2型)的毒性进行分析。比较不同的药物对肿瘤相关巨噬细胞(M2型)的抑制，结果见图7。图7显示，含有乳糖基的药物(S1)相对其他的连接方式更容易被巨噬细胞吞噬和激活。而化合物a索拉菲尼因为不是靶向激活药物，也具有毒性。
由此可见，分子定点靶向导致高激活和高效连接体具有特殊的促进肿瘤相关巨噬细胞(M2型)吞噬和激活药物的作用，从而抑制肿瘤相关巨噬细胞(M2型)。
实施例17：化合物S4-S6、S9-S12和S15-S18在CT26治疗模型中的药效和免疫治疗
按照实施例15构建CT26免疫治疗模型，并测试化合物S4-S6、S9-S12和S15-S18在CT26治疗模型中的药效和免疫治疗效果，结果如下表8所示。
表8
Figure PCTCN2018072766-appb-000039
结果与讨论：在CT26治疗模型中，考察了其他化合物的肿瘤抑制作用以及免疫治疗特性。从数据可以看出，与溶媒和阳性对照组相比，其他化合物也具有良好的抑瘤作用和抑制复发作用。在流式细胞术分析结果中，S7-S18化合物给药组中的CD8+Tcell比例较阳性对照组也有明显上升的现象，说明分子定点靶向导致高激活和高效具有使机体免疫力增加，刺激免疫的作用。

Claims (10)

  1. 下式A所示的化合物或其药学上可接受的盐：
    乳糖酸残基-XAN-PABC-Z  (式A)
    式中，
    X为极性和非极性不带电荷的氨基酸，如丙氨酸、缬氨酸或苏氨酸；
    A为丙氨酸；
    N为天冬酰胺；
    PABC为-NH-苯基-CH 2-O-；和
    Z为药物分子；
    其中，乳糖酸残基、XAN以及PABC相互间通过酰胺键相连；PABC与Z以酯基，即-O-C(O)-相连。
  2. 如权利要求1所述的化合物或其药学上可接受的盐，其特征在于，所述药物分子选自：阿霉素、达拉非尼、多韦替尼、莫特塞尼和下式B所示的索拉菲尼衍生物：
    Figure PCTCN2018072766-appb-100001
    式中，R为H或卤素；
    优选地，式B化合物选自化合物a和化合物b，即：
    Figure PCTCN2018072766-appb-100002
  3. 如权利要求1或2所述的化合物或其药学上可接受的盐，其特征在于，所述式A化合物具有下式I所示的结构：
    Figure PCTCN2018072766-appb-100003
    式I中，X和Z如权利要求1或2所述。
  4. 如权利要求1所述的化合物或其药学上可接受的盐，其特征在于，所述式A或式I化合物具有下式II、III或IV所示结构：
    Figure PCTCN2018072766-appb-100004
    其中，Z如权利要求1或2所述。
  5. 如权利要求1所述的化合物或其药学上可接受的盐，其特征在于，所述化合物 选自：
    Figure PCTCN2018072766-appb-100005
    Figure PCTCN2018072766-appb-100006
    Figure PCTCN2018072766-appb-100007
    Figure PCTCN2018072766-appb-100008
  6. 一种药物组合物，其特征在于，所述药物组合物含有权利要求1－5中任一项所述的化合物或其药学上可接受的盐，和药学上可接受的载体。
  7. 权利要求1－5中任一项所述的化合物或其药学上可接受的盐在制备治疗癌症或癌细胞转移用的药物中的应用，或在制备免疫治疗药物中的应用。
  8. 如权利要求7所述的应用，其特征在于，
    所述癌症选自：肝癌、肾癌、甲状腺癌、结肠直肠癌、膀胱癌、脑癌、乳腺癌、宫颈癌、直肠癌、食管癌、肺癌、鼻咽癌、胰腺癌、前列腺癌、皮肤癌、胃癌、子宫癌、卵巢癌、睾丸癌、血癌、恶性淋巴瘤、纤维素肉瘤、软组织肉瘤、成骨肉瘤、横纹肌肉瘤、尤文肉瘤、肾母细胞瘤、神经母细胞瘤、甲状腺癌和头颈部鳞癌；优选地，所述肺癌为支气管肺癌，包括未分化小细胞性和非小细胞性；所述血癌为慢性或急性白血病，包括淋巴细胞性和粒细胞性白血病；
    所述免疫治疗药物用于刺激T细胞的繁殖和对病灶的侵入、抑制肿瘤相关巨噬细胞和/或促进刺激免疫反应。
  9. 下式B所示的化合物：
    Figure PCTCN2018072766-appb-100009
    式中，R为H或卤素；
    优选地，式B化合物选自以下化合物a和化合物b：
    Figure PCTCN2018072766-appb-100010
  10. 下式C所示的化合物：
    乳糖酸残基-XAN-PABC’(式C)
    式中，
    X为极性和非极性不带电荷的氨基酸，如丙氨酸、缬氨酸或苏氨酸；
    A为丙氨酸；
    N为天冬酰胺；
    PABC’为-NH-苯基-CH 2-OH；
    优选地，乳糖酸残基、XAN和PABC’相互间通过酰胺键相连；
    优选地，所述式C具有下式C-1所示结构：
    Figure PCTCN2018072766-appb-100011
PCT/CN2018/072766 2017-01-17 2018-01-16 分子定点靶向和激活的激酶抑制剂的制备和用途 WO2018133766A1 (zh)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA3050345A CA3050345A1 (en) 2017-01-17 2018-01-16 Preparation and application of molecular site-directed and activated kinase inhibitors
AU2018209534A AU2018209534B2 (en) 2017-01-17 2018-01-16 Preparation and use of molecular site targeted and activated kinase inhibitor
US16/478,826 US11078232B2 (en) 2017-01-17 2018-01-16 Preparation and use of molecular site targeted and activated kinase inhibitor
EP18741988.2A EP3572420B1 (en) 2017-01-17 2018-01-16 Preparation and use of molecular site targeted and activated kinase inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710037230.9 2017-01-17
CN201710037230.9A CN108314703B (zh) 2017-01-17 2017-01-17 分子定点靶向和激活的激酶抑制剂的制备和用途

Publications (1)

Publication Number Publication Date
WO2018133766A1 true WO2018133766A1 (zh) 2018-07-26

Family

ID=62891360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/072766 WO2018133766A1 (zh) 2017-01-17 2018-01-16 分子定点靶向和激活的激酶抑制剂的制备和用途

Country Status (6)

Country Link
US (1) US11078232B2 (zh)
EP (1) EP3572420B1 (zh)
CN (1) CN108314703B (zh)
AU (1) AU2018209534B2 (zh)
CA (1) CA3050345A1 (zh)
WO (1) WO2018133766A1 (zh)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
US20080019918A1 (en) * 2004-09-10 2008-01-24 Takao Aoki Medicinal Preparation
WO2016026458A1 (zh) * 2014-08-22 2016-02-25 亚飞（上海）生物医药科技有限公司 一种肿瘤微环境特异激活的小分子靶向偶联体及其用途
CN105792850A (zh) * 2013-12-05 2016-07-20 念·吴 聚合物-碳水化合物的缀合物的药物转递技术
CN106344930A (zh) * 2015-07-16 2017-01-25 亚飞（上海）生物医药科技有限公司 分子定点靶向和激活的短肽阿霉素的制备和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218519B1 (en) * 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
US8158590B2 (en) * 2005-08-05 2012-04-17 Syntarga B.V. Triazole-containing releasable linkers, conjugates thereof, and methods of preparation
WO2008115263A2 (en) * 2007-03-20 2008-09-25 Curis, Inc. Raf kinase inhibitors containing a zinc binding moiety
CN101259284A (zh) * 2008-04-15 2008-09-10 华东师范大学 一种基于树形聚合物肝靶向抗癌纳米前药系统、制备及用途
CN101732721B (zh) * 2009-01-15 2012-06-13 中国科学技术大学 一种生物相容性纳米颗粒及其作为药物输送载体的应用
CN102863557A (zh) * 2012-10-12 2013-01-09 苏州大学 乳糖酸修饰的脂肪酸-三甲基壳聚糖聚合物制备方法及应用
JP6539729B2 (ja) * 2014-06-03 2019-07-03 ジアリー・ファーマシューティカルズ・インコーポレイテッドＪｉａｒａｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ペプチド−薬物複合体
EP3166638A1 (en) * 2014-06-13 2017-05-17 Glykos Finland Oy Payload-polymer-protein conjugates
CN104147612B (zh) * 2014-08-22 2017-05-24 亚飞（上海）生物医药科技有限公司 一种肿瘤微环境特异激活的小分子靶向偶联体及其用途
CN104800845B (zh) * 2015-01-28 2017-12-29 东华大学 一种具有肝癌细胞靶向性的二硫化钼载药纳米片的制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113274A2 (en) * 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
US20080019918A1 (en) * 2004-09-10 2008-01-24 Takao Aoki Medicinal Preparation
CN105792850A (zh) * 2013-12-05 2016-07-20 念·吴 聚合物-碳水化合物的缀合物的药物转递技术
WO2016026458A1 (zh) * 2014-08-22 2016-02-25 亚飞（上海）生物医药科技有限公司 一种肿瘤微环境特异激活的小分子靶向偶联体及其用途
CN106344930A (zh) * 2015-07-16 2017-01-25 亚飞（上海）生物医药科技有限公司 分子定点靶向和激活的短肽阿霉素的制备和用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1985, MACK PUBLISHING COMPANY
See also references of EP3572420A4

Also Published As

Publication number Publication date
EP3572420B1 (en) 2022-03-09
CN108314703A (zh) 2018-07-24
AU2018209534A1 (en) 2019-08-29
US11078232B2 (en) 2021-08-03
US20200140485A1 (en) 2020-05-07
EP3572420A1 (en) 2019-11-27
AU2018209534B2 (en) 2022-03-17
EP3572420A4 (en) 2020-11-04
CN108314703B (zh) 2022-02-01
CA3050345A1 (en) 2018-07-26

Similar Documents

Publication Publication Date Title
EA021757B1 (ru) Фармацевтические комбинации, содержащий их набор, применение этих комбинаций и способ лечения заболеваний, связанных с клеточной пролиферацией, миграцией или апоптозом клеток миеломы или с ангиогенезом
WO2021164765A1 (zh) 靶向递送和激活的免疫刺激性偶联复合物的制备和用途
JP2008531617A (ja) 蛋白質結合性アントラサイクリンペプチド誘導体、およびそれを含む医薬
JPWO2008081537A1 (ja) Ｌａｔ１阻害活性を有する芳香族アミノ酸誘導体、それを含有するｌａｔ１阻害活性剤及びその製造方法
CN112717141B (zh) 一种酸敏感靶多肽多柔比星偶联物及其合成方法和应用
JP2020535171A (ja) 去勢抵抗性前立腺癌
CN112915211B (zh) 一种pd-l1靶向肽药物偶联物及其合成方法和应用
WO2018133766A1 (zh) 分子定点靶向和激活的激酶抑制剂的制备和用途
US20240238434A1 (en) Use of medicament in treatment of tumor disease
WO2022100535A1 (zh) 一种抗肿瘤药物组合物及其应用
CN104262455B (zh) 肿瘤微环境靶向激活的紫杉醇衍生物及其制备和用途
CN106344930B (zh) 分子定点靶向和激活的短肽阿霉素的制备和用途
WO2024175042A1 (zh) 药物偶联物治疗肿瘤疾病的用途及方法
CN111732631B (zh) 一种多肽及其在制备治疗和预防肿瘤的药物中的应用
CN118436800B (zh) 靶向kras的多肽与小分子的偶联物及其抗癌应用
WO2023050037A1 (zh) 一种胞外亲环素抑制剂及其应用
TW202434202A (zh) 藥物偶聯物治療腫瘤疾病的用途及方法
CN118221742A (zh) 一类含四价铂的sting激动剂及其应用
CN117126072A (zh) 一种含酯链pd-1/pd-l1小分子抑制剂及其制备方法和应用
CN117959459A (zh) 肿瘤微环境激活的药物偶联物及抗体药物偶联物
CN114437151A (zh) 白蛋白结合型喜树碱衍生物前药及其制备方法与应用
CN115252603A (zh) indisulam在制备治疗膀胱癌的药物中的应用
KR20230042650A (ko) 면역반응을 조절하기 위한 약학적 조성물
AU2022338478A1 (en) Improvement of tumor immunogenicity by means of splicing-controlling compound
CN116925084A (zh) 对肿瘤过表达的细胞周期调节蛋白wee1有双重抑制作用的化合物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18741988

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3050345

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018741988

Country of ref document: EP

Effective date: 20190819

ENP Entry into the national phase

Ref document number: 2018209534

Country of ref document: AU

Date of ref document: 20180116

Kind code of ref document: A